CLABSI

Teleflex Awarded Peripheral Access Agreement with Premier, Inc.

Retrieved on: 
Tuesday, December 5, 2023

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc.

Key Points: 
  • WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc.
  • Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products.
  • Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines.
  • “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications1-7,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular.

Covalon’s VALGuard Gains Prestigious Recognition in the British Journal of Nursing

Retrieved on: 
Wednesday, November 15, 2023

“We are deeply grateful to the British Journal of Nursing for featuring this important work.

Key Points: 
  • “We are deeply grateful to the British Journal of Nursing for featuring this important work.
  • “It’s an honor to see Covalon’s VALGuard being recognized by such a respected journal.
  • A novel, transparent line guard (VALGuard) protects CVAD hubs from gross contamination.
  • British Journal of Nursing.

New Hospital Safety Grades from The Leapfrog Group Find Improved Infection Rates Following Major Spike During COVID-19 Pandemic

Retrieved on: 
Monday, November 6, 2023

WASHINGTON, Nov. 6, 2023 /PRNewswire/ -- The Leapfrog Group, an independent national nonprofit driving a movement for patient safety, today released its fall 2023 Hospital Safety Grades, assigning a letter grade to nearly 3,000 general hospitals on how well they prevent medical errors, accidents and infections. The latest grades show hospitals reducing health care-acquired infections (HAIs) post-pandemic after significant increases in infection rates during the COVID-19 pandemic. This cycle, nearly 30% of hospitals earned an "A," 24% earned a "B," 39% earned a "C," 7% earned a "D" and less than 1% earned an "F."

Key Points: 
  • The latest grades show hospitals reducing health care-acquired infections (HAIs) post-pandemic after significant increases in infection rates during the COVID-19 pandemic.
  • The Leapfrog Hospital Safety Grade also includes five patient experience measures that evidence suggests are closely associated with patient safety issues.
  • The Leapfrog Hospital Safety Grade is the only hospital ratings program based exclusively on hospital prevention of medical errors and harms to patients.
  • For more information about the Hospital Safety Grades, including details on individual hospital grades and state rankings, please visit HospitalSafetyGrade.org .

Access Vascular Highlights New Bacterial Adhesion Data at AVA 2023

Retrieved on: 
Tuesday, October 17, 2023

Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).

Key Points: 
  • Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced findings from a new, in vitro study showing a significant reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters (PICC) and midline catheters with AVI’s MIMIX™ hydrophilic biomaterial (HBM).
  • The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.
  • These findings are consistent with previously reported in vitro data on thrombus accumulation, based on platelet count,iv,v with the HBM catheter.
  • “These results highlight the potential for catheters made from MIMIX™ to reduce bacterial adhesion, which often leads to central-line associated bloodstream infections (CLABSI) and has devastating implications for already sick patients,” said James Biggins, CEO of Access Vascular.

United States Medical Sterilizers Market Insights Report 2023-2028: Next-Gen Sterilization Methods on the Rise, Transforming the Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023

The "US Medical Sterilizers Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Medical Sterilizers Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • US Medical Sterilizers Market is projected to reach a value of $3.43 billion by 2028 from $2.13 billion in 2022, growing at a CAGR of 8.3%
    This report provides an in-depth analysis of the complete US Medical Sterilizers market.
  • The Medical Sterilizers market is one of the growing markets in the US.
  • The rise of new products like printed organs and semi-synthetic implants are demanding unique sterilization methods in the market.

Teleflex Announces Extension of Arrow™ ErgoPack™ Complete System to Hemodialysis and Large Bore Central Venous Catheters

Retrieved on: 
Monday, August 21, 2023

This update is intended to streamline insertion workflow for clinicians and provide more options to suit their needs.

Key Points: 
  • This update is intended to streamline insertion workflow for clinicians and provide more options to suit their needs.
  • Clinicians can choose between Arrowg+ard Blue™ Hemodialysis or Large Bore lines in this expanded kit configuration, with a variety of French sizes, lumens, and lengths.
  • The Arrow™ ErgoPack™ Complete System expansion includes a variety of clinician-inspired updates:
    Option of 3M™ Tegaderm™ CHG I.V.
  • Advanced Securement Dressing with BioPatch® Protective Disk
    “Max barrier kits like the Arrow™ ErgoPack™ Complete System provide clinicians with the necessary components they need for their Acute Hemodialysis and Large Bore insertions.

Premier Medical Journal Spotlights Covalon’s VALGUARD: A Novel Solution to Long-Standing Problem of Protecting Vascular Access Sites

Retrieved on: 
Tuesday, July 18, 2023

“At Covalon we’re incredibly grateful to JAVA and Darcy for bringing greater awareness to how Covalon’s VALGuard product can protect and empower more patients receiving vascular access care.

Key Points: 
  • “At Covalon we’re incredibly grateful to JAVA and Darcy for bringing greater awareness to how Covalon’s VALGuard product can protect and empower more patients receiving vascular access care.
  • The majority of CLABSIs are preventable, and strengthening infection protection bundles with improved practices and new technology is a proven approach.
  • Doellman, D. Guarding the Central venous Access Device: A New Solution for an Old Problem.
  • Journal of the Association for Vascular Access.

Breakthrough Solution for Fragile Skin: Covalon’s IV Clear® Dressing Recommended by Physicians at a Top 10 U.S. Children’s Hospital and Epidermolysis Bullosa Center of Excellence

Retrieved on: 
Tuesday, June 13, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230613612362/en/
    Covalon's IV Clear® is the world's only dual antimicrobial silicone adhesive vascular access dressing.
  • (Photo: Business Wire)
    EB, sometimes known as “Butterfly Skin”, is a little-known skin disorder with a prevalence of 1 in 20,000 births.
  • There is no cure to the debilitating connective tissue disorder that causes extremely fragile skin prone to blisters and tears from minor friction.
  • EB patients often require surgical procedures, and securement of intravenous (IV) catheters and peripheral nerve catheters on EB patients present major challenges to anesthesiologists.

Teleflex Awarded Agreements with Premier, Inc.

Retrieved on: 
Thursday, June 1, 2023

WAYNE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc.

Key Points: 
  • WAYNE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc.
  • Effective July 1st, 2023, the new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Central Venous and Arterial Vascular Access products.
  • Premier has awarded Teleflex a national agreement for Hemodynamic Monitoring Products and Accessories, a national agreement for Central Venous Access, a Sole Source for AscenDrive Central Venous Access, and a Sole Source for SURPASS Central Venous Access.
  • “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications like infection and thrombosis,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular.

Intellego Technologies Partners With HAI Solutions for a Novel Application of Ultraviolet Photochromic Ink for an Intravenous Port Disinfection Technology to Mitigate Risk of Contamination

Retrieved on: 
Monday, May 22, 2023

Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access.

Key Points: 
  • Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access.
  • The partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component in HAI Solutions' QIKcap™ technology to offer visible and verifiable IV port protection and provide confidence that the needle-free connector has been disinfected.
  • (Photo: Business Wire)
    The QIKcap Disinfection Device™ is a patented, handheld UV-C tool that is designed to irradiate the surface of an intravenous connector and intravenous access points to prevent microbial ingress.
  • Our partnership with HAI Solutions demonstrates our commitment to life-saving technologies and promoting the safety, efficacy and efficiency of ultraviolet disinfection applications.”
    "We are thrilled to announce our new strategic partnership with Intellego Technologies,” said Nicholas Perrenoud, CEO of HAI Solutions.